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We investigate crosstalk between cancer cells and
stromal myeloid cells. We find that Lewis lung carci-
noma cells significantly induce PPARb/d activity in
myeloid cells in vitro and in vivo.Myeloid cell-specific
knockout of PPARb/d results in impaired growth of
implanted tumors, and this is restored by adoptive
transfer of wild-type myeloid cells. We find that
IL-10 is a downstream effector of PPARb/d and facil-
itates tumor cell invasion and angiogenesis. This
observation is supported by the finding that the
CD11blowIL-10+ pro-tumoral myeloid cell is scarcely
detected in tumors from myeloid-cell-specific
PPARb/d knockout mice, where vessel densities
are also decreased. Fatty acid synthase (FASN) is
shown to be an upstream regulator of PPARb/d in
myeloid cells and is induced by M-CSF secreted
from tumor cells. Our study gives insight into how
cancer cells influence myeloid stromal cells to get a
pro-tumoral phenotype.INTRODUCTION
Tumor-infiltrating myeloid cells are involved in tumor develop-
ment, progression, and resistance to conventional treatment
(Biswas and Mantovani, 2010; Karin et al., 2006; Mantovani
et al., 2008; Pollard, 2009) through various mechanisms
including mutagenesis, angiogenesis, lymphangiogenesis (Mur-
doch et al., 2008), suppression of adaptive immunity (Kuang1614 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The Authoret al., 2009), remodeling of the extracellular matrix, and invasion
and metastasis of tumor cells (Lin et al., 2001, 2006). The molec-
ular regulators that determine the diverse pro-tumoral pheno-
types of tumor myeloid cells can be an excellent target of a novel
anti-cancer therapy. However, themolecular determinants of the
diverse pro-tumoral phenotypes in tumor microenvironment
have been incompletely understood, though there are several
candidates such as NF-kappaB (Hagemann et al., 2008),
STAT3 (Kujawski et al., 2008), c-Myc (Pello et al., 2012), and
Notch (Wang et al., 2010), mostly for immunosuppressive phe-
notypes of myeloid cells.
Nuclear receptor peroxisome-proliferator-activated receptor-
beta/delta (PPARb/d), a key metabolic transcription factor, plays
a crucial role in tumorigenesis and tumor progression. However,
it is still debated whether PPARb/d is pro-tumoral or anti-tumoral
(Peters and Gonzalez, 2009; Zuo et al., 2009). Prior work has pri-
marily focused on the role of PPARb/d in the malignant cells
themselves and not in the tumor stromal cells. Recent two
reports suggested that PPARb/d might be the key regulator of
tumor angiogenesis (Abdollahi et al., 2007; Mu¨ller-Bru¨sselbach
et al., 2007). However, the detailed mechanism of PPARb/d-
dependent tumor angiogenesis has not been elucidated.
Tumor-infiltrating myeloid cells have been reported to be most
significant cells among the multiple stromal cell types in solid
tumors for fostering tumor angiogenesis (Condeelis and Pollard,
2006). Activation of PPARb/d regulates anti-inflammatory phe-
notypes of myeloid cells in other biological contexts such as in
atherosclerosis and obesity (Han et al., 2008; Kang et al.,
2008; Lee et al., 2003; Odegaard et al., 2008). Thus, we hypoth-
esized that PPARb/d activation in myeloid cells of tumor micro-
environment would promote its pro-tumoral function to facilitate
tumor invasion and angiogenesis.s
Figure 1. Activation of PPARb/d in Myeloid Cells by Lewis Lung Carcinoma
(A) IF staining of tumor tissue from C57BL/6mice. Blue, nucleus; green, CD11b+myeloid cells; green arrow, myeloid cell nucleus; magenta, PPARb/d; red, CD31+
endothelial cells; red arrow, endothelial cell nucleus; white broken line, capillary wall; scale bars, 10 mm.
(B) PPARb/dmRNA expression in endothelial cells (ECs) and myeloid cells (MCs) from LLC tumor (TEC and TMC) and normal lung tissue (LEC and LMC; n = 6).
Error bars represent SEM.
(C) ADRP mRNA expression in ECs and MCs from LLC tumor and normal lung tissue (n = 6). Error bars, SEM.
(D) Effect of LCM on PPARb/d activation in MC assessed by trans-activation assay (n = 3). PPARb/d ligand binds with ligand-binding domain (LBD) and activates
GAL4 DNA-binding domain (DBD), which results in luciferase expression. RLU, relative light units. Error bars, SEM.
(E) Effect of LCM on PPARb/d mRNA expression in MCs as determined by real-time PCR (n = 8). Error bars, SEM.
(F) Effect of LCM on PPARb/d binding at arginase I promoter in MCs as determined by ChiP assay. Representative figure of three independent experiments.
See also Figure S1.RESULTS
Cancer Cells Activate PPARb/d in Tumor Myeloid Cells
In mouse model of Lewis lung carcinoma (LLC), PPARb/d was
substantially expressed in CD11b+ tumor myeloid cells as well
as in malignant cells themselves, whereas it was marginally ex-
pressed in CD31+ tumor endothelial cells (Figure 1A). Myeloid
cells also in other various human cancer tissues showed
PPARb/d expression, whereas CD31+ endothelial cells rarely ex-
pressed it (Figures S1A–S1H). To quantify this observation and to
evaluate the activity of PPARb/d, we measured the expression
and activity of PPARb/d in myeloid cells and endothelial cells iso-
lated from tumors and normal lung tissue (Figures S1I and S1J).
The expression of PPARb/d in myeloid cells was higher than that
of endothelial cells. Its expression in myeloid cells was different
depending on tissue, lower in lung cancer than in normal lung
(Figure 1B). However, the activity of PPARb/d or expression of
ADRP was remarkably higher in tumor myeloid cells than in
myeloid cells from normal tissue (Figure 1C). Interesting findingCellwas discrepancy of expression amount versus activity of
PPARb/d between myeloid cells in lung cancer versus normal
lung (Figures 1B and 1C): lower expression amount and higher
activity of PPARb/d in myeloid cells of lung cancer than ones of
normal lung. To identify the mechanism, we tested the effect of
conditioned media of LLC cells (LCM) on PPARb/d activation in
myeloid cells (Raw 264.7) using PPARb/d trans-activation assay.
LCM-treated myeloid cells significantly increased PPARb/d
trans-activation (Figure 1D). Chromatin immuno-precipitation
assay showed increased binding of PPARb/d to the promoter
of arginase I, a representative marker of myeloid cell activation,
whereas expression of PPARb/d itself was not changed by LCM
treatment (Figures 1E and 1F).
The Role of PPARb/d in Myeloid Cell for Tumor Growth
and Angiogenesis
Because prior report suggested that myeloid cells comprise
most of the tumor infiltrates that derived from the bone marrow
(BM) (Ahn and Brown, 2008), we introduced BM transplantationReports 10, 1614–1625, March 10, 2015 ª2015 The Authors 1615
Figure 2. The Role of PPARb/d in MCs for Tumor Growth and Angiogenesis
(A) LLC tumor volume growth in PPARb/d WT and KO BMT mice (n = 8 or 9 in each group). Error bars, SEM.
(B) LLC tumor weight in PPARb/d WT and KO BMT mice at 2 weeks after implantation (n = 8 or 9 in each group). Error bars, SEM.
(C) LLC tumor growth in mice receiving BMT from PPARb/dWT or KO mice with adoptive transfer of BMDMs from PPARb/d WT or KO mice (n = 4 or 5 in each
group). KOBM, PPARb/d KO BMT mice; KOMC, adoptive transfer of PPARb/d KO BMDMs; WTBM, PPARb/d WT BMT mice; WTMC, adoptive transfer of
PPARb/d WT BMDMs. Error bars, SEM.
(D) LLC tumor weight in PPARb/d WT and KO BMT mice with adoptive transfer of PPARb/d WT or KO BMDMs (n = 4 or 5 in each group). Error bars, SEM.
(E) Proportion of necrotic area in tumors of mice receiving BMT from PPARb/dWT or KO mice. Representative figures of H&E staining of the tumors. N indicates
necrotic area. The scale bar represents 1 mm (n = 3 or 4). Error bars, SEM.
(F) CVDs of tumors in mice receiving BMT from PPARb/dWT or KO mice. CVDs were determined as the area of CD31 positive per total area (%). The scale bar
represents 100 mm (n = 8 in each group). Error bars, SEM.(BMT)model using PPARb/d knockout (KO) or wild-type (WT) BM
to test the specific effect of PPARb/d activation in myeloid cells.
LLC tumor growth was significantly attenuated in mice trans-
planted with BM from PPARb/d KO mice. Tumor volumes in
mice receiving BMT from PPARb/d WT or KO mice were
229.45 ± 27.93 mm3 versus 107.94 ± 20.44 mm3 (p = 0.0010)
at day 14, and tumor weights were 122.2 ± 18.2 mg versus
45.0 ± 10.2 mg (p = 0.0028) at day 14 (Figures 2A and 2B). Our
result suggests that PPARb/d in myeloid cells is critical in tumor
progression. To validate this observation, we performed a
reverse experiment by transferring BM-derived myeloid cells
(BMDMs) of PPARb/d WT or KO mice into mice receiving BMT
from PPARb/d KO or WT mice along with LLC implantation.
Tumors in mice receiving BMT from PPARb/d WT mice showed
almost the same tumor volume and weight, regardless of the
type of the transferred macrophages (WT BMT mice with ‘‘WT
BMDMs’’ 213.14 ± 17.57 mm3 and 110.0 ± 5.7 mg versus WT
BMT mice with ‘‘KO BMDMs’’ 195.93 ± 7.25 mm3 and 120.0 ±
8.6 mg at day 14; Figures 2C and 2D). On the other hand, the
tumor growth in mice receiving BMT from PPARb/d KO mice re-
mained poor, even after the adoptive transfer of BMDMs from
PPARb/d KO mice (114.19 ± 18.68 mm3 and 72.5 ± 8.5 mg at
day 14; p < 0.01), whereas the attenuated tumor growth in
mice receiving BMT from PPARb/d KO mice was fully reversed1616 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The Authorby the adoptive transfer of BMDMs from PPARb/d WT mice
(203.35 ± 23.50 mm3 and 127.5 ± 9.5 mg at day 14; Figures 2C
and 2D). In addition, it appeared that retarded growth of tumor
was associated with broader necrosis in the tumor. The tumor
of poor growth in mice receiving BMT from PPARb/d KO mice
showed larger areas of necrosis in the tumors than those in
mice receiving BMT from PPARb/d WT mice (KO BMT mice
47.61% ± 1.19% versus WT BMT mice 35.14% ± 2.30%;
p = 0.0034; Figure 2E). Capillary vessel density (CVD) was also
significantly lower in tumor of mice receiving BM from PPARb/d
KO mice than in those of mice receiving BM from PPARb/d WT
mice (CVD in KO BMT tumor 1.15% ± 0.17% versus WT BMT
tumor 2.42% ± 0.22%; p = 0.0004; Figure 2F). This observation
supports our hypothesis that PPARb/d in tumormyeloid cells has
a key role in tumor growth and angiogenesis.
PPARb/d Induces Pro-tumoral Phenotype in Tumor
Myeloid Cells
To address how PPARb/d controls tumor myeloid cells to stimu-
late tumor growth and angiogenesis, we evaluated the survival,
infiltration, and phenotype changes of myeloid cells in tumor
microenvironment. In vitro results demonstrated that, when
treated with LCM, BMDMs from PPARb/d WT or KO mice did
not exhibit any difference in survival (Figure 3A). Also, thes
Figure 3. Induction of Pro-tumoral Phenotype in MC by PPARb/d
(A) Comparison of PPARb/dWT and KOMC survival in vitro. Percentage of viable or apoptotic MC percentage was determined by annexin V/7-AAC staining and
FACS analysis. n.s. indicates no significance (n = 4 or 5). Error bars, SEM.
(B) Comparison of PPARb/d WT and KO MC infiltration capacity in vitro. MC infiltration capacity was evaluated by transwell migration assay. n.s. indicates no
significance (n = 5). Error bars, SEM.
(C) Effect of PPARb/d deficiency on expression of pro-tumoral and anti-tumoral factors in MCs treated with serum-free media (SFM) or LLC-cell-conditioned
media (LCM). The mRNA expressions of arginase I, IL-10, IL-12p35, VEGF-A, MMP-9, TGF-b, and EGF were determined by real-time PCR (n = 7 for arginase I,
IL-10, VEGF-A, and MMP-9; n = 4 for TGF-b and EGF; and n = 11 for IL-12p35). Error bars, SEM.
(D) Distribution and density of CD11blowIL-10+ pro-tumoral MCs in tumor tissues of mice receiving BMT from PPARb/dWT or KOmice. Histological sections were
stained with antibodies against CD11b (green) and IL-10 (red). N indicates necrotic area. The scale bars represent 500 mm for the upper line and 50 mm for the
lower line (n = 8 in each group). CD11blowIL-10+ cells were quantified from FACS analysis of tumors and determined as the percentage of CD11blowIL-10+ cells
from total CD11b+ MCs; * indicates p < 0.05; n = 8 in each group from two independent experiment. Error bars, SEM.
See also Figure S2 and Table S1.infiltrative capacity of BMDMs toward LLC cells was not affected
by PPARb/d deficiency (Figure 3B). However, expression of pro-
tumoral factors such as arginase I and IL-10 was significantly
attenuated in BMDMs of PPARb/d KO mice compared with
BMDMs of PPARb/dWTmice (Figure 3C). Conversely, an impor-
tant anti-tumoral and anti-angiogenic cytokine, IL-12 was higher
in BMDMs of PPARb/d KO mice than in those of PPARb/d WT
mice. Instead, PPARb/d deficiency did not affect other well-
known pro-tumoral factors such as MMP-9, VEGF-A, TGF-b,
and EGF (Figure 3C). NOS2 was similarly produced in WT and
KO BMDM (Figure S2). This implies that PPARb/d activation in-
duces pro-tumoral phenotype in myeloid cells. These findings
were also validated in the tumor tissues of our BMTmodel. There
were two distinct types of CD11b+ myeloid cells in the tumor
stroma: CD11blowIL-10+ cells andCD11bhighIL-10 cells (Figures
S3A–S3C). CD11blowIL-10+ cells or pro-tumoral myeloid cellsCell(Mantovani and Locati, 2009; Mantovani et al., 2002) were
more abundant in tumors from PPARb/d WT BMT mice
compared with those from PPARb/d KO BMT mice (Figure 3D).
In the tumors fromPPARb/dWTBMTmice, most of CD11b+ cells
were CD11blowIL-10+ and they were evenly distributed across
the whole tumor tissue without necrosis. In contrast, in the
tumors from PPARb/d KOBMTmice, there were a larger number
of CD11bhighIL-10 cells, which were mostly placed in the
necrotic tissue (Figures S3D–S3F). These in vivo results are high-
ly consistent with the in vitro observations and support the
conclusion that PPARb/d is a key determinant of pro-tumoral
phenotype in myeloid cells of tumor. To further characterize
the identity of tumor myeloid cells, we performed FACS analysis
for lineage markers of CD11blowIL-10+ cells and found that the
cells are F4/80+GR-1Ly6G tumor-associated macrophages
(Figures 4A and 4B). As IL-10 and arginase I represent M2Reports 10, 1614–1625, March 10, 2015 ª2015 The Authors 1617
Figure 4. Characterization of IL-10-Producing Tumor MCs
LLC were implanted to wild-type C57 mice. After 2 weeks, the tumors were FACS analyzed for characterization of IL-10-producing tumor MCs.
(A) CD11blowIL-10+ cells were analyzed for lineage markers: GR-1, F4/80, CD11c, Ly6C, and Ly6G (black histogram). The expressions of lineage markers were
compared to CD11bhighIL-10 counterpart (gray histogram). Representative result of n = 8 in three independent experiments.
(B) The red-colored histogram represents IL-10 expression of the total CD11b+ MCs. The expression of IL-10 in the marker-positive myeloid population (black
histogram) is compared to the expression of IL-10 in the marker-negativemyeloid population (gray histogram). Representative result of n = 8 in three independent
experiments.
(C) Tumor cells were co-stained with IL-10, CD11b, F4/80, and CD206. IL-10 expression (histogram) of the leukocyte gate (top), CD11b+ tumor myeloid gate
(second row), CD11b+F4/80+ tumor-associated macrophage (TAM) (third row) gate and the CD11b+F4/80+CD206+ M2-activated TAMs are depicted. Repre-
sentative result of n = 6 in two independent experiments.
See also Figures S3 and S4.phenotype of macrophages, we checked additional surface
marker of macrophages and found that CD206+ M2-activated
TAMs represented population with the highest IL-10 expression
(Figures 4C and S4A). Those CD206+ M2-activated TAMs were
mainly located at the non-necrotic area of the LLC tumor and
showed increased PPARb/d expression (Figures S4B and
S4C). Proportion of the M2-activated TAMs was significantly
smaller in tumors of the PPARb/d KO BMT mice (Figure S4D).
PPARb/d Activation in Myeloid Cells Stimulates Cancer
Cell Invasion and Angiogenesis in IL-10-Dependent
Manner
Then, how does the phenotype of myeloid cells, represented as
overexpression of IL-10 by PPARb/d (Figure S5), affect tumor
cells and tumor angiogenesis? We further evaluated the effect
of PPARb/d activation and IL-10 upregulation on tumor cell sur-1618 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The Authorvival, invasion, and angiogenesis in vitro. PPARb/d deficiency in
BMDMs had no effect on tumor cell apoptosis or survival in
co-culture experiment (Figure 5A) but significantly suppressed
the tumor cell migration through collagen gel, compared with
PPARb/dWT BMDMs (Figure 5B). Supplementation of recombi-
nant IL-10 recovered tumor cell invasion that was attenuated by
co-culture with PPARb/d KO BMDMs, whereas neutralization of
IL-10 distinctively blocked tumor cell invasion augmented by
co-culture with WT BMDMs (Figure 5C).
In the in vitro assay for tube formation and migration of endo-
thelial cells by co-culture supernatant of tumor cells and BMDMs
from either PPARb/d WT or KO mice, the angiogenic capacity
was significantly decreased in the supernatant from co-culture
of PPARb/d KO BMDMs and tumor cells, compared with the su-
pernatant from PPARb/d WT BMDMs co-cultured with tumor
cells. The retarded angiogenic effect of PPARb/d KO myeloids
Figure 5. The Mechanism of Pro-tumoral MCs to Enhance Tumor Cell Invasion and Angiogenesis
(A) Effect of myeloid-cell-specific PPARb/d on tumor cell survival. Percentage of viable or apoptotic MC percentage was determined by annexin V/7-AAC staining
and FACS analysis. n.s. indicates no significance (n = 4). Error bars, SEM.
(B) Effect of myeloid-cell-specific PPARb/d on tumor cell invasion. Tumor cell invasion capacity was evaluated by collagen gel invasion assay as described in
schematic illustration. Green cell indicates GFP-tagged 3LL tumor cells, and red cell indicates PKH-Red-tagged BMDMs. The scale bar represents 50 mm (n = 3).
Error bars, SEM.
(C) IL-10-mediated effect of myeloid-cell-specific PPARb/d on tumor cell invasion. Abs indicates antibodies. Green cell indicates 3LL tumor cells (GFP tagged),
and red cell indicates PKH-Red-tagged BMDMs. Ve indicates control IgG or vehicle. The scale bar represents 50 mm (n = 3 or 4). Error bars, SEM.
(D) IL-10-mediated effect of myeloid-cell-specific PPARb/d on EC tube formation and migration. EC tube formation in Matrigel was determined by total tube
length (mm) or complete tube counts per area (/mm2). EC migration function was tested by scratch-wound assay, and migration potential was determined by
average of migration distance (mm). Ve indicates control IgG or vehicle (n = 6). Error bars, SEM.
See also Figure S5.cells was rescued by the supplementation of recombinant IL-10,
whereas normal angiogenic effect of PPARb/dWT myeloid cells
was attenuated by the neutralization of IL-10 (Figure 5D). These
results demonstrate that IL-10 is the key mediator of PPARb/d-
dependent function of myeloid cells in tumor microenvironment,
promoting tumor cell invasion and tumor angiogenesis.
Mechanism How Cancer Cells Activate PPARb/d in
Myeloid Cells: Paracrine Network Involving M-CSF
and FASN
Using arginase I mRNA expression as a marker, we screened
possible endogenous ligands of PPARb/d in tumormicroenviron-
ment: free fatty acids; prostaglandins; and arachidonic acids.
Because the ligands could originate from either cancer cells
(exogenously) or myeloid cells (endogenously), we treated the in-
hibitors of each enzyme to cancer cells before LCM preparationCellor directly to BMDMs (Figure S6A). Here, only fatty acid synthase
(FASN) inhibitor directly treated to myeloid cells blocked argi-
nase I upregulation caused by LCM (Figure 6A). To verify this
result, we made FASN knockdown LLC cells and FASN knock-
down myeloid cells (Raw 264.7) using sh-FASN lentivirus (Fig-
ures S6B and S6C) and observed that LCM-induced PPARb/d
activation is blocked by FASN knockdown in myeloid cells, but
not by FASN knockdown in cancer cells (Figure 6B). In agree-
ment with this finding, FASN expression was significantly
increased in myeloid cells by LCM (Figures 6C and 6D). This
result implies that endogenous ligands derived from FASN in
myeloid cells can be a key regulator of PPARb/d activity in the
context of tumor myeloid cells.
Then, to find the candidate messengers in tumor microenvi-
ronment thatmediates FASNexpression andPPARb/d activation
in myeloid cells, we analyzed LCM regarding several secretaryReports 10, 1614–1625, March 10, 2015 ª2015 The Authors 1619
Figure 6. Paracrine Mechanism How Tumor Cells Activate PPARb/d in MCs
(A) Arginase I expression in MC after blocking the production of free fatty acids (FFAs), arachidonic acids (AAs), or prostaglandins (PGs) in LLC cells and MCs by
inhibitor of FASN, cPLA2, or COX (n = 4–7). LAA, AAs-depleted LCM; L+AACOCF3, LCM supplemented with AACOCF3; L+cerulenin, LCM supplemented with
cerulenin; LFFA, FFAs-depleted LCM; L+indomethacin, LCM supplementedwith indomethacin; LPG, PG-depleted LCM. *indicates p < 0.05. Error bars, SEM.
Detailed scheme of the experiment is described in Figure S6.
(B) Effect of FASN knockdown in LLC cells or MCs on PPARb/d activation in MC determined by trans-activation assay (n = 4–6). FASN was knockdown by
sh-FASN lentiviral transduction into LLC cells or Raw 264.7 MCs, and sh-scramble (sh-Sc) lentivirus was used as control. * indicates p < 0.05. Error bars, SEM.
(C) Effect of LCM on FASN expression in MCs (n = 3). * indicates p < 0.05. Error bars, SEM.
(D) IF staining against FASN in MCs cultured in SFM or LCM. LCM significantly induced FASN protein expression in MCs. Representative figure of three inde-
pendent experiments. The scale bars represent 20 mm.
(E) Analysis of LCM regarding tumor-derived factors that are known to be involved in activation of MCs using ELISA, pg/ml (n = 3).
(F) Effect of M-CSF (50 ng/ml) or M-CSF receptor inhibitor Ki20227 (1 mM) on FASN expression in MCs, by real-time PCR. M-CSF as well as LCM significantly
increased FASN mRNA expression in MCs, and Ki20227 reversed the effect of LCM (n = 4–6). * indicates p < 0.05. Error bars, SEM.
(G) Effect of M-CSF (50 ng/ml) or M-CSF receptor inhibitor Ki20227 (1 mM) on PPARb/d activity in MCs, by PPARb/d trans-activation assay. M-CSF as well as LCM
significantly activated PPARb/d in MCs, and Ki20227 reversed the effect of LCM (n = 3 or 4). * indicates p < 0.05. Error bars, SEM.
See also Figures S6 and S7.factors that have been shown to be important in activation of
macrophages or PPARb/d. We found that macrophage colony-
stimulating factor (M-CSF) was markedly secreted by LLC cells
(Figure 6E), and FASN expression was significantly increased
by M-CSF treatment in myeloid cells, whereas blocking M-CSF
in LCM with Ki20227, a specific inhibitor of M-CSF receptor,
reversed the induction of FASN expression by LCM treatment
(Figure 6F). Moreover, M-CSF treatment resulted in PPARb/d
activation in trans-activation assay, whereas PPARb/d activation
by LCMwas blocked by Ki20227 (Figure 6G). These results alto-
gether indicate that M-CSF secreted from LLC cells induces
FASN expression inmyeloid cells, leading to PPARb/d activation.
DISCUSSION
Here, we demonstrate that PPARb/d activation in tumor myeloid
cells control their pro-tumoral phenotype, particularly the
expression of IL-10, and stimulates tumor angiogenesis and ma-
trix invasion of malignant cell. The physiological relevance of this
pathway was demonstrated in LLC tumor model with PPARb/d1620 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The AuthorWT and KO BMT mice, which revealed that PPARb/d deficiency
in tumor myeloid cell attenuated tumor growth and angiogen-
esis. Finally, we found that PPARb/d activation in tumor myeloid
cells was induced by the paracrine network between M-CSF
from cancer cells and induction of FASN in myeloid cells.
Importance of PPARb/d in Myeloid Cells to
Control Tumor Growth
Previous studies of PPARb/d in cancer paid attention exclusively
to the role of PPARb/d in malignant cells and carcinogenesis
(Gupta et al., 2004; Peters and Gonzalez, 2009; Peters et al.,
2008). But there have been two studies that distinguished the
effect of PPARb/d in malignant cells from stromal cells and eval-
uated the effect of PPARb/d in tumor stromal cells. In both
studies, they made tumor model with PPARb/d WT/KO mice
implanted with syngeneic PPARb/d WT LLC cells. Then they
showed that PPARb/d-deficient stromal cells delayed tumor
growth and attenuated functional tumor angiogenesis (Abdollahi
et al., 2007; Mu¨ller-Bru¨sselbach et al., 2007). However, the two
studies focused only on tumor endothelial cells based ons
previous reports on the role of PPARb/d in endothelial function.
(Brunelli et al., 2007; Fan et al., 2008; Ghosh et al., 2007; Liou
et al., 2006; Piqueras et al., 2007). Here, we found that the
expression and the activity of PPARb/d were lower in tumor
endothelial cell compared to tumor myeloid cell. In vivo tumor
model of PPARb/d WT or KO BMT mice and adoptive transfer
of PPARb/d WT or KO myeloid cells demonstrated that PPARb/
d in myeloid cell is critical in tumor growth and angiogenesis.
Our study also suggests that the difference of tumor angiogen-
esis in PPARb/dWT and KOmice is a result of altered phenotype
of tumor myeloid cells. It provides strong evidence that PPARb/
d plays a significant role in stromal cells, especially in tumor
myeloid cell, and gives us further insight of the molecule’s role
in tumor angiogenesis.
Importance of PPARb/d in Myeloid Cells to Induce
M2-like Pro-tumoral Phenotype
Previous studies argue that the immune suppressive and angio-
genic phenotype of infiltrating myeloid cells are crucial determi-
nants of tumor progression (Condeelis and Pollard, 2006;
Pollard, 2004). Classically, the phenotype was simply classified
into M1, the pro-inflammatory microbactericidal and tumoricidal
phenotype, and M2, the immune-regulatory phenotype involved
in tissue remodeling and tumor progression (Sica and Manto-
vani, 2012). Tumor-associated monocytes-macrophages are
roughly considered to presentM2-like phenotype, which is asso-
ciatedwith the promotion of tumor growth and tissue remodeling
(Galdiero et al., 2013). In present study, BMDMs treated with
LCM increased expression of IL-10, arginase I, and VEGF
whereas decreased expression of IL-12. Induction of IL-10 and
arginase I as well as suppression of IL-12 were PPARb/d-depen-
dent, whereas induction of VEGF was not dependent on
PPARb/d. ChiP result confirmed that LCM increased binding of
PPARb/d to PPRE of arginase I. To our knowledge, this is the first
report investigating the role of PPARb/d regulating the M2-like
pro-tumoral phenotype of tumor-associated myeloid cells.
IL-10 dampens the immune response to pathogens and is a
well-known anti-inflammatory product of T-helper 2 cells (Sar-
aiva and O’Garra, 2010). In tumor, the increased production of
IL-10 frommyeloid cells promotes immune suppression through
activation of STAT3 (Kinjyo et al., 2006; Kujawski et al., 2008). In
another report, IL-10-producing LLC cell line showed more
rapidly growing tumor with increased vessel density in mice
compared to control (Dace et al., 2008; Mocellin et al., 2003;
Zeng et al., 2010). In vitro result of our study suggests that
IL-10 might exert direct effect on endothelial cell migration and
tube formation. Overall, pro-tumoral effect of IL-10 seems to
be mediated not only by suppression of immune surveillance
against tumor but also by enhancement of angiogenesis.
Upstream Regulator of PPARb/d in Myeloid Cells
Several eicosanoids and saturated and unsaturated fatty acids
were suggested to be natural ligands of PPARb/d (Forman
et al., 1997; Krey et al., 1997; Xu et al., 1999; Yu et al., 1995).
PPARb/d activation in myeloid cells has been described in previ-
ous reports. The suggested relevant ligands of PPARb/d included
VLDL-particle-derived fatty acids (Chawla et al., 2003), adipose-
tissue-derived fatty acids (Odegaard et al., 2008), and apoptotic-Cellcell-derived fatty acids (Mukundan et al., 2009). All the previous
reports focused on exogenous ligands and the potential mecha-
nism to transport the ligands to the cytoplasm of myeloid cell.
Because increased production of de novo fatty acids was known
as a hallmark of cancer cell transformation (Menendez and Lupu,
2007), we initially postulated that fatty acids derived from cancer
cells would act as a significant mediator of interaction between
myeloid cells and tumor. Unexpectedly, FASN knockdown in
LLC did not exert any effect on PPARb/d activation in myeloid
cells. Instead, FASN knockdown in myeloid cells themselves
significantly reduced PPARb/d activation by the LCM. This pro-
vides the first evidence that ‘‘endogenous FASN’’ in myeloid
cell is necessary for the activation of PPARb/d in tumor myeloid
cell. In colorectal carcinoma, endogenously synthesized prosta-
glandin I2 and 13-S-hydroxyoctadecadienoic acid were reported
to modulate PPARb/d activity (Gupta et al., 2000; Shureiqi et al.,
2003). Recently, the importance of FASN and endogenously syn-
thesized ‘‘new fat’’ was highlighted in mouse liver to activate
another PPAR family. In the report, FASN was shown to produce
long-chain fatty acid, which was then converted to specific
endogenous ligand to activate PPARa (Chakravarthy et al.,
2009). In this regard, we suggest that FASN-derived new fat or
its derivatives may activate PPARb/d. Further study is needed
to identify the physiologically relevant endogenous ligand of
PPARb/d in myeloid cells.
Mechanism of Cancer Cells to Tame Myeloid Cells:
Paracrine Network Involving M-CSF to FASN
TAMs, in terms of metabolism, are expected to downregulate
FASN expression due to carbohydrate deprivation from exces-
sive glucose utilization by the surrounding malignant cancer
cells. In this regard, we speculate that the M-CSF signaling plays
the critical role in the unexpected upregulation of FASN in TAMs.
Previous studies reported the role of cancer-derived M-CSF in
the differentiation of myeloid cell phenotype. M-CSF is the key
cytokine that induces myeloid cell to have the immunosup-
pressed and tissue-trophic phenotype (Mantovani et al., 2002;
Pollard, 2004). The signal pathways activated by M-CSF include
PI3K/Akt, MAPK, and JAK/STAT pathway (Mouchemore and
Pixley, 2012). These are the same pathways reported to be
responsible for the dysregulated overexpression of FASN in
malignant cells (Menendez and Lupu, 2007). Regarding down-
stream effectors, M-CSF stimulated production of IL-10 and
CCL2 whereas suppressing IL-12 and IL-23 (Fleetwood et al.,
2007; Lacey et al., 2012). However, the exact mechanism how
M-CSF regulates wide range of downstream effectors is still
uncovered. In the present study, M-CSF from cancer cells
increased the expression of FASN and activated PPARb/d to
increase IL-10 expression and suppress IL-12 expression.
Generalization and Application
We asked whether the above finding was generalizable to
different solid tumors. When we compared the growth of various
cancer cell lines in PPARb/dWT and KO BMTmice (Figure S7A),
only the B16-F10 melanoma cell line showed impaired tumor
growth like LLC cell line. Interestingly, only the supernatants of
LLC and B16-F10 upregulated the expression of FASN and sub-
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Figure 7. Crosstalk between Tumor and
Stromal Cells in Tumor Microenvironment
M-CSF secreted from tumor cells induces FASN in
MCs, leading to PPARb/d activation, phenotypic
change, and secretion of IL-10 from MCs. IL-10
from MCs in turn stimulates tumor cell invasion as
well as angiogenesis by ECs migration and prolif-
eration.(Figures S7B and S7C). We speculate that there might be a spe-
cific phenotype of cancer that influences tumor myeloid cells
via the FASN-PPARb/d pathway. As synthetic antagonist of
PPARb/d is available, characterization of the specific phenotype
and its marker in human cancer would be a promising strategy
to target the tumor microenvironment and impair cancer
progression.
Taken as awhole, the present study identifies a new liaison be-
tween malignant cells and stromal cells. M-CSF from cancer
cells induces FASN-PPARb/d pathway in stromal cells, leading
to secretion of IL-10 and tumor progression (Figure 7).
EXPERIMENTAL PROCEDURES
Animal Experiments
We used PPARb/dKOmice with the exon 8 of the gene disrupted as previously
described (Peters et al., 2000). BM cells were isolated from PPARb/dWT or KO
mice and underwent lineage depletion (CD3, CD11b, CD45R/B220, Gr-1, and
TER119;BDBiosciences)withmagnetic-activatedcell sorting (MACS) (Miltenyi
Biotec). Recipient mice received lethal dose of 6.5 + 6.5 Gy irradiationwith 4-hr
interval. Lineage-depleted hematopoietic stem cells (1 3 105 cells/ recipient)
were injected into recipientmicewithin 24 hr after the second irradiation. Donor
marrowwas allowed to repopulate for 4weeks, and themicewere used for LLC
tumormodel. All the animal protocol was approved by the Experimental Animal
Committee of Seoul National University. 7 3 105 LLC cells at exponential
growth were suspended in 70 ml of growth-factor-reducedMatrigel (BD Biosci-
ences) and injected subcutaneously in the left flankof indicatedmice. For adop-
tive transfer experiments, equal number of PPARb/d WT or KO BMDMs were
mixed with LLC cells in 70 ml of Matrigel. Tumor sizes (length [L] and width
[W]) were measured using calipers, and tumor volume was calculated using
the equation volume = L 3 W2/2. Tumor was dissected, and the weight was
measured 2 weeks after implantation. All the animal experiments of the study
were approved by the Institutional Animal Care and Use Committee (IACUC)
in Seoul National University Hospital (IACUC approval no. SNU-140630-4).
Sorting of Endothelial Cells and Myeloid Cells from LLC Tumor
and Normal Lung Tissue
Two weeks after LLC cells were injected into Tie-2 GFP transgenic mice as
above, tumors were surgically removed, minced, and digested with collage-1622 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The Authorsnase I (1 mg/ml) and DNase I (1 mg/ml; Roche) in
HBSS for 30 min at 37C and passed through
40-mm cell strainer. Dissociated single cells were
stained with CD11b-APC antibody (BD Biosci-
ences) and sorted with FACSAria based on their
fluorescence (GFP: Tie-2+ endothelial cells;
PerCP: CD11b+ myeloid cells; Figure S2).
Macrophage Isolation and Culture
in Conditioned Media
BMDMs were isolated and cultured as described
previously (Weischenfeldt and Porse, 2008).
Briefly, marrow was flushed from femur and tibia
of indicated mice, passed through 40-mm cellstrainer, and incubated in hypotonic RBC lysis solution. The cells were plated
at a density of 13 106/ml and cultured in RPMI containing 10% FBS and 15%
L-929-conditioned media for 7 days. At day 8, differentiated macrophages
were used for subsequent experiments. LCM was prepared as previously
described (Kim et al., 2009). Briefly, 12 hr after 2 3 106 LLC had been plated
on a 10-cm culture dish, growth media was replaced by 8 ml of serum-free
RPMI 1640. The conditioned media was collected for next 18 hr, centrifuged
for 10 min at 3,000 g, and passed through 0.45-mm pore filter. Serum-free
RPMI 1640 medium (SFM) was incubated for the same duration and passed
through the filter to serve as control media. SFM and LCM were treated for
18 hr to evaluate macrophage phenotype gene and PPAR b/d expression
and for 8 hr for FASN expression and ChIP assay. To block each enzyme
activity of LLC during LCM preparation, the following concentrations of inhib-
itors were treated to LLC cells 1 hr before the start of LCM preparation: ceru-
lenin (5 mg/ml; Sigma-Aldrich); AACOCF3 (10 mM; Tocris Bioscience); and
indomethacin (1 mM; Sigma-Aldrich). To block the enzyme activities of
BMDM during LCM stimulation, the same concentration of each inhibitor
was mixed to the LCM.
Immunofluorescence Staining of Tumor Tissue and BMDM
The tumor tissues were embedded in OCT compound and frozen in isopen-
tane cooled with liquid nitrogen. The frozen tissue was cut into 8-mm section
and fixed with acetone or 1% PFA. Blocking was done with 5% normal goat
serum with 1% BSA and 1% FcR blocker (Miltenyi Biotec). Rat anti-CD31
antibodies, rat anti-IL-10 antibodies (eBioscience), rabbit anti-PPAR b/d anti-
bodies (Santa Cruz Biotechnology), biotinylated anti-CD11b antibodies (BD
Biosciences), and FITC-tagged anti-CD31 antibodies (BD Biosciences) were
used as primary antibodies. The nuclei were counterstained with Sytox blue
(Invitrogen). To evaluate CVDs, CD31-positive area per total area was quanti-
fied at six random fields of each section. To quantify CD11blowIL-10+ cells infil-
tration, IL-10+ cells were automatically counted and manually confirmed to be
CD11blow. LSM 710 microscopes and ZEN 2010 Software (Carl Zeiss) were
used for image acquisition and Image-Pro Plus (MediaCybernetics) for
quantification.
FACS Analysis of Tumor-Infiltrating Myeloid Cells
Tumors of LLC injected into PPARb/d WT or KO BMT mice were prepared to
single-cell suspension as described above at 2 weeks. FITC-tagged anti-
CD11b; PE-tagged anti-IL-10; PerCP-Cy5.5-tagged anti-F4/80; and APC-
tagged anti-Ly6C, anti-Ly6G, anti-CD11c, anti-CD86, anti-MHC class II, and
anti-CD206 antibodies were used for analysis.
Annexin V and 7-AAD FACS Analysis for Cell Survival
BMDMs were tagged with PKH-26 kit (Sigma-Aldrich) according to manu-
facturer’s protocol to distinguish it from LLC cells during the co-culture
experiments. Equal number of BMDMs and LLC cells (each 3 3 105 cells)
were co-cultured for 24 hr in SFM. The co-cultured cells were stained
with annexin V-FITC and 7-AAD, and the percentage of apoptotic and
necrotic cells were quantified with FACS Canto-II (BD Biosciences). LLC
cells and BMDMs were separately gated based on PKH-26 signal (585/42
[PE] detector). The percentage of apoptotic (annexin V-FITC; 530/330
[FITC] detector) and necrotic/late apoptotic (7-AAD; 670LP [PerCP-Cy5.5,
PERCP] detector) cells were calculated in each gate. For experiments of
PPARb/d WT or KO BMDM survival, the BMDMs were cultured for 24 hr
in SFM, stained with annexin V-FITC and 7-AAD, and analyzed as above
except for PE gating.
Invasion/Infiltration Assay
The 24-well insert system (BDBiosciences) was used to assess BMDM infiltra-
tion capacity. LLC cells and PKH-26-stained BMDMs were plated in 24-well
bottom plate and on 8-mm pore inserts, respectively. After 12 hr, the inserts
were placed on the LLC culture. After 24 hr, BMDM infiltration was quantified
as the red fluorescent cell counts at the bottom of the insert.
For the assessment of LLC cell invasion capacity affected by BMDMs, we
modified previously described vertical collagen gel chamber invasion assay
(Yoon et al., 2005). GFP-tagged LLC cells were added on PKH-26-stained
BMDMs already plated on optical 8-well dish (Ibidi). The co-cultured cells
were then covered with 150 ml of collagen (Millipore) and GFR-reduced Matri-
gel (BD Biosciences) mixture (1:1) and kept at 37C until the gel polymerized.
After 1 hr, 100 ml of RPMI 10% FBS medium was added on the top of collagen
gel to attract the cells upward in each well. The vertical upward migration of
green (LLC) and red (BMDM) cells were quantified using the z stack imaging
acquired with Zeiss LSM 710 confocal microscopy.
Endothelial Cell Function Assay
Matrigel tube formation (Hur et al., 2007) and scratch wound assay (Lee et al.,
2009) were done as previously described with slight modification of the proto-
col. For tube formation, 23 104 human umbilical vein endothelial cells (Lonza)
were seeded on the Matrigel-coated chamber slide with indicated conditioned
media treated with recombinant mouse IL-10 (10 ng/ml), anti-IL-10-blocking
antibodies (eBioscience; 0.5 mg/ml), or protein/antibody control. After 12 hr,
four random fields were taken and the count of complete tube formation per
unit area and total length of tube in the field were quantified. For migration
assay with scratch-wound model, MS1 (mouse endothelial cell line; ATCC)
cells were cultured in 6-well dishes to confluence. The monolayers were
scraped through the middle of the dish by using a sterile disposable rubber
policeman. After wounding, monolayers were immediately washed and incu-
bated with indicated conditioned media and recombinant mouse IL-10
(10 ng/ml), anti-IL-10-blocking antibody (0.5 mg/ml), or protein/antibody con-
trol. After 24 hr, migration of the cells was quantified bymeasuring average dis-
tance of maximal migration into denuded area at five points of regular interval.
Image-Pro Plus was used for quantification.
PPARb/d Trans-activation Assay
The ligand-binding domain of mouse PPARb/d was fused to the DNA-binding
domain of the yeast transcription factor Gal4 under the control of the SV40 pro-
moter, and the plasmid also encoded the UAS-firefly luciferase reporter under
the control of the Gal4 DNA response element (Bility et al., 2004). Mono-
macrophage cell line RAW 264.7 was transfected with plasmid DNA used
with Neon electroporation system (Invitrogen; Guignet and Meyer, 2008).
The electroporation condition was 3 3 105 cells in 10 ml with single pulse of
voltage 1,680 V over 20 ms. 6 3 105 cells from two electroporations were
pooled and plated on a 6-well dish with media supplemented with 20% FBS
and 15% L-media. After 24 hr of stabilization, the transfected cells were
treated with different conditioned media for 24 hr and the luciferase activity
was measured. As the reporter produced firefly luciferase, we used constitu-
tively expressed Renilla luciferase (pRL-TK; Promega) for transfection control
and quantified luciferase activity with dual luciferase assay kit (Promega) ac-
cording to manufacturer’s protocol.CellFASN Knockdown with Short-Hairpin Lentivirus
To reduce endogenous FASN expression, pLL3.7 lentiviral vector (Addgene)
that expresses shRNA under the mouse U6 promoter was utilized. A CMV-
EGFP reporter cassette is included in the vector tomonitor expression. We fol-
lowed previous protocol to produce lentiviral vectors (Rubinson et al., 2003).
The consensus sequences were provided by The RNAi Consortium. The
sequence for FASN knockdown was 50-GCTGGTCGTTTCTCCATTAAA-30
and shRNA sequence for scramble (Sc) control was 50-CAACAAGATGAAG
AGCACCAA-30. Sub-confluent RAW 264.7 and LLC cells were transducted
with indicated lentivirus and limit diluted in 96-well to get the single clone
with consistent GFP expression. The resulting clones were expanded, and
the FASN knockdown was confirmed with real-time PCR.
Statistical Analysis
All data are presented as mean ± SE. Student’s t test or paired t test was per-
formed for inter-group comparisons. One-way ANOVAwith Bonferroni correc-
tion was used for multiple-group comparisons. SPSS version 16.0 was used
for analysis, and a p value of <0.05 was considered statistically significant.
See also Supplemental Experimental Procedures.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.02.024.
AUTHOR CONTRIBUTIONS
J.P. provided execution of experiments, data analysis and interpretation, and
drafting of the manuscript; S.E.L. provided conception and design of experi-
ments, data analysis and interpretation, and drafting of the manuscript; J.H.
provided execution of experiments, data analysis and interpretation, and draft-
ing of the manuscript; E.B.H. provided execution of experiments and data
analysis; J.-I.C. provided execution of experiments and data analysis;
J.-M.Y. provided data analysis and interpretation and critical review of the
manuscript; J.-Y.K. provided execution of experiments, data analysis and
interpretation, and critical review of the manuscript; Y.-C.K. provided data
analysis and interpretation and critical review of the manuscript; H.-J.C. pro-
vided conception and design of experiments and critical review of the manu-
script; J.M.P. provided data analysis and interpretation and critical review of
the manuscript; S.-B.R. provided key experiment materials and critical review
of themanuscript; Y.T.K. provided key experimentmaterials and critical review
of the manuscript; and H.-S.K. provided conception and design of experi-
ments, data analysis and interpretation, and critical review of the manuscript.
ACKNOWLEDGMENTS
We thank Ms. H.W. Jung for her excellent assistance in animal experiments.
This study was supported by grants from the Bio &Medical Technology Devel-
opment Program (2010-0020258) of Korea National Research Foundation
(NRF); the Innovative Research Institute for Cell Therapy (A062260) funded
by Ministry of Health & Welfare (MHW); and the Korea Health Technology
R&DProject (HI12C16910000, HI14C1277, and HI12C0199) through the Korea
Health Industry Development Institute, funded by MHW.
Received: May 13, 2014
Revised: January 6, 2015
Accepted: February 4, 2015
Published: March 5, 2015
REFERENCES
Abdollahi, A., Schwager, C., Kleeff, J., Esposito, I., Domhan, S., Peschke, P.,
Hauser, K., Hahnfeldt, P., Hlatky, L., Debus, J., et al. (2007). Transcriptional
network governing the angiogenic switch in human pancreatic cancer. Proc.
Natl. Acad. Sci. USA 104, 12890–12895.Reports 10, 1614–1625, March 10, 2015 ª2015 The Authors 1623
Ahn, G.O., and Brown, J.M. (2008). Matrix metalloproteinase-9 is required for
tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived
myelomonocytic cells. Cancer Cell 13, 193–205.
Bility, M.T., Thompson, J.T., McKee, R.H., David, R.M., Butala, J.H., Vanden
Heuvel, J.P., and Peters, J.M. (2004). Activation of mouse and human perox-
isome proliferator-activated receptors (PPARs) by phthalate monoesters.
Toxicol. Sci. 82, 170–182.
Biswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction
with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896.
Brunelli, L., Cieslik, K.A., Alcorn, J.L., Vatta, M., and Baldini, A. (2007). Perox-
isome proliferator-activated receptor-delta upregulates 14-3-3 epsilon in
human endothelial cells via CCAAT/enhancer binding protein-beta. Circ.
Res. 100, e59–e71.
Chakravarthy, M.V., Lodhi, I.J., Yin, L., Malapaka, R.R., Xu, H.E., Turk, J., and
Semenkovich, C.F. (2009). Identification of a physiologically relevant endoge-
nous ligand for PPARalpha in liver. Cell 138, 476–488.
Chawla, A., Lee, C.H., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J., Kang,
H., and Evans, R.M. (2003). PPARdelta is a very low-density lipoprotein sensor
in macrophages. Proc. Natl. Acad. Sci. USA 100, 1268–1273.
Condeelis, J., and Pollard, J.W. (2006). Macrophages: obligate partners for
tumor cell migration, invasion, and metastasis. Cell 124, 263–266.
Dace, D.S., Khan, A.A., Kelly, J., and Apte, R.S. (2008). Interleukin-10
promotes pathological angiogenesis by regulating macrophage response to
hypoxia during development. PLoS ONE 3, e3381.
Fan, Y., Wang, Y., Tang, Z., Zhang, H., Qin, X., Zhu, Y., Guan, Y., Wang, X.,
Staels, B., Chien, S., and Wang, N. (2008). Suppression of pro-inflammatory
adhesion molecules by PPAR-delta in human vascular endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 28, 315–321.
Fleetwood, A.J., Lawrence, T., Hamilton, J.A., and Cook, A.D. (2007).
Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage
CSF-dependent macrophage phenotypes display differences in cytokine pro-
files and transcription factor activities: implications for CSF blockade in inflam-
mation. J. Immunol. 178, 5245–5252.
Forman, B.M., Chen, J., and Evans, R.M. (1997). Hypolipidemic drugs,
polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome pro-
liferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 94,
4312–4317.
Galdiero, M.R., Garlanda, C., Jaillon, S., Marone, G., andMantovani, A. (2013).
Tumor associated macrophages and neutrophils in tumor progression. J. Cell.
Physiol. 228, 1404–1412.
Ghosh, M., Wang, H., Ai, Y., Romeo, E., Luyendyk, J.P., Peters, J.M.,
Mackman, N., Dey, S.K., and Hla, T. (2007). COX-2 suppresses tissue factor
expression via endocannabinoid-directed PPARdelta activation. J. Exp.
Med. 204, 2053–2061.
Guignet, E.G., andMeyer, T. (2008). Suspended-drop electroporation for high-
throughput delivery of biomolecules into cells. Nat. Methods 5, 393–395.
Gupta, R.A., Tan, J., Krause, W.F., Geraci, M.W., Willson, T.M., Dey, S.K., and
DuBois, R.N. (2000). Prostacyclin-mediated activation of peroxisome prolifer-
ator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. USA
97, 13275–13280.
Gupta, R.A., Wang, D., Katkuri, S., Wang, H., Dey, S.K., and DuBois, R.N.
(2004). Activation of nuclear hormone receptor peroxisome proliferator-acti-
vated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 10,
245–247.
Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson,
R.G., Robinson, S.C., and Balkwill, F.R. (2008). ‘‘Re-educating’’ tumor-associ-
ated macrophages by targeting NF-kappaB. J. Exp. Med. 205, 1261–1268.
Han, J.K., Lee, H.S., Yang, H.M., Hur, J., Jun, S.I., Kim, J.Y., Cho, C.H., Koh,
G.Y., Peters, J.M., Park, K.W., et al. (2008). Peroxisome proliferator-activated
receptor-delta agonist enhances vasculogenesis by regulating endothelial
progenitor cells through genomic and nongenomic activations of the phospha-
tidylinositol 3-kinase/Akt pathway. Circulation 118, 1021–1033.1624 Cell Reports 10, 1614–1625, March 10, 2015 ª2015 The AuthorHur, J., Yang, H.-M., Yoon, C.-H., Lee, C.-S., Park, K.-W., Kim, J.-H., Kim,
T.-Y., Kim, J.-Y., Kang, H.-J., Chae, I.-H., et al. (2007). Identification of a novel
role of T cells in postnatal vasculogenesis: characterization of endothelial pro-
genitor cell colonies. Circulation 116, 1671–1682.
Kang, K., Reilly, S.M., Karabacak, V., Gangl, M.R., Fitzgerald, K., Hatano, B.,
and Lee, C.H. (2008). Adipocyte-derived Th2 cytokines and myeloid
PPARdelta regulate macrophage polarization and insulin sensitivity. Cell
Metab. 7, 485–495.
Karin, M., Lawrence, T., and Nizet, V. (2006). Innate immunity gone awry: link-
ingmicrobial infections to chronic inflammation and cancer. Cell 124, 823–835.
Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y.,
Luo, J.L., and Karin, M. (2009). Carcinoma-produced factors activate myeloid
cells through TLR2 to stimulate metastasis. Nature 457, 102–106.
Kinjyo, I., Inoue, H., Hamano, S., Fukuyama, S., Yoshimura, T., Koga, K.,
Takaki, H., Himeno, K., Takaesu, G., Kobayashi, T., and Yoshimura, A.
(2006). Loss of SOCS3 in T helper cells resulted in reduced immune responses
and hyperproduction of interleukin 10 and transforming growth factor-beta 1.
J. Exp. Med. 203, 1021–1031.
Krey, G., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M.G.,
andWahli, W. (1997). Fatty acids, eicosanoids, and hypolipidemic agents iden-
tified as ligands of peroxisome proliferator-activated receptors by coactivator-
dependent receptor ligand assay. Mol. Endocrinol. 11, 779–791.
Kuang, D.M., Zhao, Q., Peng, C., Xu, J., Zhang, J.P., Wu, C., and Zheng, L.
(2009). Activated monocytes in peritumoral stroma of hepatocellular carci-
noma foster immune privilege and disease progression through PD-L1.
J. Exp. Med. 206, 1327–1337.
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., and Yu, H.
(2008). Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.
J. Clin. Invest. 118, 3367–3377.
Lacey, D.C., Achuthan, A., Fleetwood, A.J., Dinh, H., Roiniotis, J., Scholz,
G.M., Chang, M.W., Beckman, S.K., Cook, A.D., and Hamilton, J.A. (2012).
Defining GM-CSF- and macrophage-CSF-dependent macrophage responses
by in vitro models. J. Immunol. 188, 5752–5765.
Lee, C.H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W.A., Evans, R.M.,
and Curtiss, L.K. (2003). Transcriptional repression of atherogenic inflamma-
tion: modulation by PPARdelta. Science 302, 453–457.
Lee, C.S., Kwon, Y.W., Yang, H.M., Kim, S.H., Kim, T.Y., Hur, J., Park, K.W.,
Cho, H.J., Kang, H.J., Park, Y.B., and Kim, H.S. (2009). Newmechanism of ro-
siglitazone to reduce neointimal hyperplasia: activation of glycogen synthase
kinase-3beta followed by inhibition of MMP-9. Arterioscler. Thromb. Vasc.
Biol. 29, 472–479.
Lin, E.Y., Nguyen, A.V., Russell, R.G., and Pollard, J.W. (2001). Colony-
stimulating factor 1 promotes progression of mammary tumors to malignancy.
J. Exp. Med. 193, 727–740.
Lin, E.Y., Li, J.F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D.A., Qian, H., Xue,
X.N., and Pollard, J.W. (2006). Macrophages regulate the angiogenic switch in
a mouse model of breast cancer. Cancer Res. 66, 11238–11246.
Liou, J.Y., Lee, S., Ghelani, D., Matijevic-Aleksic, N., and Wu, K.K. (2006).
Protection of endothelial survival by peroxisome proliferator-activated recep-
tor-delta mediated 14-3-3 upregulation. Arterioscler. Thromb. Vasc. Biol. 26,
1481–1487.
Mantovani, A., and Locati, M. (2009). Orchestration of macrophage polariza-
tion. Blood 114, 3135–3136.
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macro-
phage polarization: tumor-associated macrophages as a paradigm for polar-
ized M2 mononuclear phagocytes. Trends Immunol. 23, 549–555.
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related
inflammation. Nature 454, 436–444.
Menendez, J.A., and Lupu, R. (2007). Fatty acid synthase and the lipogenic
phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777.
Mocellin, S., Panelli, M.C.,Wang, E., Nagorsen, D., andMarincola, F.M. (2003).
The dual role of IL-10. Trends Immunol. 24, 36–43.s
Mouchemore, K.A., and Pixley, F.J. (2012). CSF-1 signaling in macrophages:
pleiotrophy through phosphotyrosine-based signaling pathways. Crit. Rev.
Clin. Lab. Sci. 49, 49–61.
Mukundan, L., Odegaard, J.I., Morel, C.R., Heredia, J.E., Mwangi, J.W.,
Ricardo-Gonzalez, R.R., Goh, Y.P., Eagle, A.R., Dunn, S.E., Awakuni, J.U.,
et al. (2009). PPAR-delta senses and orchestrates clearance of apoptotic cells
to promote tolerance. Nat. Med. 15, 1266–1272.
Mu¨ller-Bru¨sselbach, S., Ko¨mhoff, M., Rieck, M., Meissner, W., Kaddatz, K.,
Adamkiewicz, J., Keil, B., Klose, K.J., Moll, R., Burdick, A.D., et al. (2007).
Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR-
beta-deficient mice. EMBO J. 26, 3686–3698.
Murdoch, C., Muthana, M., Coffelt, S.B., and Lewis, C.E. (2008). The role of
myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8,
618–631.
Odegaard, J.I., Ricardo-Gonzalez, R.R., Red Eagle, A., Vats, D., Morel, C.R.,
Goforth, M.H., Subramanian, V., Mukundan, L., Ferrante, A.W., and Chawla,
A. (2008). Alternative M2 activation of Kupffer cells by PPARdelta ameliorates
obesity-induced insulin resistance. Cell Metab. 7, 496–507.
Pello, O.M., De Pizzol, M., Mirolo, M., Soucek, L., Zammataro, L., Amabile, A.,
Doni, A., Nebuloni, M., Swigart, L.B., Evan, G.I., et al. (2012). Role of c-MYC in
alternative activation of human macrophages and tumor-associated macro-
phage biology. Blood 119, 411–421.
Peters, J.M., and Gonzalez, F.J. (2009). Sorting out the functional role(s) of
peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in
cell proliferation and cancer. Biochim. Biophys. Acta 1796, 230–241.
Peters, J.M., Lee, S.S., Li, W., Ward, J.M., Gavrilova, O., Everett, C., Reitman,
M.L., Hudson, L.D., and Gonzalez, F.J. (2000). Growth, adipose, brain, and
skin alterations resulting from targeted disruption of the mouse peroxisome
proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20, 5119–5128.
Peters, J.M., Hollingshead, H.E., and Gonzalez, F.J. (2008). Role of peroxi-
some-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastroin-
testinal tract function and disease. Clin. Sci. 115, 107–127.
Piqueras, L., Reynolds, A.R., Hodivala-Dilke, K.M., Alfranca, A., Redondo,
J.M., Hatae, T., Tanabe, T., Warner, T.D., and Bishop-Bailey, D. (2007). Activa-
tion of PPARbeta/delta induces endothelial cell proliferation and angiogenesis.
Arterioscler. Thromb. Vasc. Biol. 27, 63–69.
Pollard, J.W. (2004). Tumour-educated macrophages promote tumour pro-
gression and metastasis. Nat. Rev. Cancer 4, 71–78.
Pollard, J.W. (2009). Trophic macrophages in development and disease. Nat.
Rev. Immunol. 9, 259–270.CellRubinson, D.A., Dillon, C.P., Kwiatkowski, A.V., Sievers, C., Yang, L., Kopinja,
J., Rooney, D.L., Zhang, M., Ihrig, M.M., McManus, M.T., et al. (2003). A lenti-
virus-based system to functionally silence genes in primary mammalian cells,
stem cells and transgenic mice by RNA interference. Nat. Genet. 33, 401–406.
Saraiva, M., and O’Garra, A. (2010). The regulation of IL-10 production by
immune cells. Nat. Rev. Immunol. 10, 170–181.
Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J.B., Leesnitzer, L.M., Morris,
J.S., Fan, H.Z., Fischer, S.M., and Lippman, S.M. (2003). The 15-lipoxygenase-
1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to
induce apoptosis in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 100,
9968–9973.
Sica, A., and Mantovani, A. (2012). Macrophage plasticity and polarization:
in vivo veritas. J. Clin. Invest. 122, 787–795.
Wang, Y.C., He, F., Feng, F., Liu, X.W., Dong, G.Y., Qin, H.Y., Hu, X.B., Zheng,
M.H., Liang, L., Feng, L., et al. (2010). Notch signaling determines the M1
versus M2 polarization of macrophages in antitumor immune responses.
Cancer Res. 70, 4840–4849.
Weischenfeldt, J., and Porse, B. (2008). Bone marrow-derived macrophages
(BMM): isolation and applications. CSH Protoc. 2008, pdb.prot5080.
Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blanchard, S.G., Brown,
P.J., Sternbach, D.D., Lehmann, J.M., Wisely, G.B., Willson, T.M., et al. (1999).
Molecular recognition of fatty acids by peroxisome proliferator-activated
receptors. Mol. Cell 3, 397–403.
Yoon, C.H., Hur, J., Park, K.W., Kim, J.H., Lee, C.S., Oh, I.Y., Kim, T.Y., Cho,
H.J., Kang, H.J., Chae, I.H., et al. (2005). Synergistic neovascularization by
mixed transplantation of early endothelial progenitor cells and late outgrowth
endothelial cells: the role of angiogenic cytokines and matrix metalloprotei-
nases. Circulation 112, 1618–1627.
Yu, K., Bayona, W., Kallen, C.B., Harding, H.P., Ravera, C.P., McMahon, G.,
Brown, M., and Lazar, M.A. (1995). Differential activation of peroxisome prolif-
erator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975–23983.
Zeng, L., O’Connor, C., Zhang, J., Kaplan, A.M., and Cohen, D.A. (2010). IL-10
promotes resistance to apoptosis and metastatic potential in lung tumor cell
lines. Cytokine 49, 294–302.
Zuo, X., Peng, Z., Moussalli, M.J., Morris, J.S., Broaddus, R.R., Fischer, S.M.,
and Shureiqi, I. (2009). Targeted genetic disruption of peroxisome proliferator-
activated receptor-delta and colonic tumorigenesis. J. Natl. Cancer Inst. 101,
762–767.Reports 10, 1614–1625, March 10, 2015 ª2015 The Authors 1625
